TNFRSF9 and non-small cell lung carcinoma: To evaluate the impact of immunotherapy on naïve NSCLC patients, we analyzed the circulating levels of CD3+, CD137+, PD1+, and Ki67+ T cells subsets (total, CD4+ and CD8+) of 48 patients before (T0) and after the first cycle of immunotherapy (T1) (Figure 1, Supplementary Figure 1).